We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.77B
1-Year Est. Return 307.72%
This Fund
S&P 500
This Quarter Est. Return
+25.89%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$161M
AUM Growth
+$94.2M
Cap. Flow
+$79.6M
Cap. Flow %
49.53%
Top 10 Hldgs %
100%
Holding
6
New
4
Increased
–
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$111M
2
KROS icon
Keros Therapeutics
KROS
+$20M
3
AMAM
Ambrx Biopharma Inc
AMAM
+$8.67M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$5.93M

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$48.9M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$53.8B
$113M 70.21%
+297,701
New +$111M
KROS icon
2
Keros Therapeutics
KROS
$211M
$20.6M 12.81%
+428,532
New +$20M
AMAM
3
DELISTED
Ambrx Biopharma Inc
AMAM
$17.2M 10.72%
+7,584,489
New +$8.67M
RXDX
4
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$10.1M 6.26%
+91,379
New +$5.93M
VTYX
5
DELISTED
Ventyx Biosciences
VTYX
– –
-1,401,123
Closed -$48.9M
KRTX
6
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-77,768
Closed -$17.5M

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
ABC
Associated Banc-Corp Green Bay, Wisconsin $3.78B AUM 21.74% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
VA
VestGen Advisors Inverness, Illinois $3.76B AUM 26.04% 1-Year Est. Return
GCC
Guardian Capital (Canada) Toronto, Ontario, Canada $3.78B AUM 33.04% 1-Year Est. Return
SB
SIG Brokerage New York $3.79B AUM 44.46% 1-Year Est. Return

Darwin Global Management's Q4 2022 Portfolio in Review

As of Q4 2022, Darwin Global Management held 6 positions worth $161M, up 142% from $66.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Darwin Global Management deployed $79.6M of net new capital in Q4 2022, opening 4 new positions. Its largest new stake was argenx: 297,701 shares worth $113M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was Ventyx Biosciences, an estimated $48.9M sold.

  • Darwin Global Management's largest Q4 2022 buy was argenx: 297,701 shares worth $113M.
  • Darwin Global Management fully exited Ventyx Biosciences in Q4 2022, selling an estimated $48.9M.
  • Darwin Global Management's ten largest holdings make up 100% of its $161M portfolio in Q4 2022.
  • Darwin Global Management opened 4 new positions and closed 2 in Q4 2022.
  • Darwin Global Management's portfolio value rose 142% quarter-over-quarter to $161M.

Based on Darwin Global Management's 13F filing for Q4 2022, filed 14 Feb 2023.